Cambrian BioPharma Inc's Form 4 filing
Faeth Therapeutics, Inc. (FTH) · filed Jun 1, 2026
- Accession no.
- 0000897069-26-001299
- Filed
- Jun 1, 2026
- Trade date
- Jun 1, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $500.5K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cambrian BioPharma IncCIK 0001797409 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | SSaleDisposed | −24,524 | $20.00F1 | −$490,480 | 130,618 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −476 | $21.14 | −$10,062.64 | 130,142 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.